concept

DOPAMINE

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DOPAMINE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

469Connections

12Hypotheses

0Analyses

50Outgoing

50Incoming

10Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	DOPAMINE
Key Genes/Proteins	AKT, ALPHA-SYNUCLEIN, ALZHEIMER, AMYLOID, APOE
Related Diseases	acetylcholine, ACETYLCHOLINE, Alzheimer'S Disease, ALZHEIMER'S DISEASE

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Dopamine Signaling Pathway

mechanism · 3237 words

→

Pathway Diagram

graph TD
    DOPAMINE["DOPAMINE"]
    DOPAMINE -->|"involved_in"| Parkinson_s_Disease["Parkinson's Disease"]
    DOPAMINE -->|"regulates"| neuronal_uptake["neuronal uptake"]
    DOPAMINE -->|"interacts"| GDNF["GDNF"]
    DOPAMINE -->|"interacts"| Substantia_Nigra["Substantia Nigra"]
    DOPAMINE -->|"treats"| diabetic_retinal_neurodegenera["diabetic retinal neurodegeneration"]
    DOPAMINE -->|"activates"| NRF2["NRF2"]
    DOPAMINE -->|"regulates"| GPX4["GPX4"]
    DOPAMINE -->|"regulates"| BDNF["BDNF"]
    DOPAMINE -->|"expressed in"| striatum["striatum"]
    COMT["COMT"] -->|"degrades"| DOPAMINE
    Atremorine["Atremorine"] -->|"interacts"| DOPAMINE
    GDNF -->|"inhibits"| DOPAMINE
    Substantia_Nigra -->|"interacts"| DOPAMINE
    levodopa["levodopa"] -->|"converts_to"| DOPAMINE

Outgoing (114)

Target	Relation	Type	Str
reward-based motivation	modulates	process	0.95
Locomotion	regulates	phenotype	0.95
Reward-Based Motivation	regulates	phenotype	0.95
Performance Monitoring	modulates	process	0.90
Parkinson's Disease	involved_in	disease	0.90
Parkinson'S Disease	associated_with	disease	0.90
endocrine functions	regulates	process	0.90
Addiction	associated_with	disease	0.90
Schizophrenia	associated_with	disease	0.90
Dopaminergic Neuron	expressed_in	cell_type	0.85
Hyperprolactinemia	associated_with	disease	0.85
Neuronal Uptake	inhibits	process	0.85
Parkinson'S Disease	protects_against	disease	0.85
A1 Astrocytes	inhibits	cell_type	0.85
BDNF	upregulates	protein	0.85
Parkinsons Disease	associated_with	disease	0.85
Depression in Parkinson's Disease	involved_in	phenotype	0.85
NFKB	inhibits	protein	0.85
A2 Astrocytes	promotes	cell_type	0.85
NLRP3	inhibits	protein	0.85
Neuronal Uptake	mediates	process	0.85
BDNF	activates	protein	0.80
Hippocampus-Dependent Learning	involved_in	process	0.80
Hyperarousal	modulates	phenotype	0.80
Circadian Clock Genes	modulates	pathway	0.75
NF-κB	regulates	pathway	0.75
GDNF	interacts_with	entity	0.70
NRF2	activates	protein	0.70
striatum	expressed_in	brain_region	0.70
BDNF	regulates	protein	0.70
ALPHA-SYNUCLEIN	activates	protein	0.70
GPX4	regulates	protein	0.70
diabetic retinal neurodegeneration	treats	disease	0.70
Substantia Nigra	interacts_with	entity	0.70
NEUROINFLAMMATION	treats	phenotype	0.70
ALZHEIMER'S DISEASE	regulates	disease	0.70
neuronal uptake	regulates	process	0.70
TH	targets	gene	0.65
LYSOSOMAL DYSFUNCTION	regulates	phenotype	0.65
LYSOSOMAL DYSFUNCTION	causes	phenotype	0.65
PARKINSON'S DISEASE	targets	disease	0.65
NEURONS	produces	cell_type	0.65
DOPAMINERGIC NEURONS	targets	cell_type	0.65
DEPRESSION	treats	disease	0.65
BDNF	causes	gene	0.65
NEURODEGENERATION	protects_against	phenotype	0.65
GABA	inhibits	phenotype	0.65
TAU	treats	protein	0.65
TH	produces	gene	0.65
CORTEX	causes	brain_region	0.65

Incoming (355)

Source	Relation	Type	Str
ALZHEIMER'S DISEASE	associated_with	disease	1.00
PARKINSON'S DISEASE	associated_with	disease	1.00
Atremorine	upregulates	compound	0.95
17035544	plays a role in regulating	paper	0.90
21176768	binds competitively with and interacts with	paper	0.90
35345678	blocks the reuptake of	paper	0.90
35345678	blocks reuptake of	paper	0.90
BDNF	associated_with	gene	0.90
Exercise	upregulates	process	0.90
ADHD	associated_with	disease	0.90
IL-6	associated_with	gene	0.90
Circadian Clock Genes	regulates	pathway	0.85
Atremorine	activates	drug	0.85
Peganum Harmala	upregulates	drug	0.85
SDA-2026-04-01-gap-20260401-225155	involves	analysis	0.85
TNF	associated_with	gene	0.82
COMT	degrades	gene	0.80
GLP-1R Agonists	upregulates	drug	0.80
Atremorine	interacts_with	drug	0.80
FNDC5	upregulates	protein	0.80
AMYLOID	associated_with	protein	0.74
LRRK2	associated_with	gene	0.74
Substantia Nigra	regulates	entity	0.70
GDNF	inhibits	entity	0.70
GDNF	activates	entity	0.70
GDNF	interacts_with	entity	0.70
GDNF	therapeutic_target	entity	0.70
ASTROCYTE	protects_against	cell_type	0.70
TH	regulates	gene	0.70
OXIDATIVE STRESS	interacts_with	phenotype	0.70
PARKIN	causes	gene	0.70
Substantia Nigra	interacts_with	entity	0.70
Substantia Nigra	activates	entity	0.70
Ginsenoside Rb1	activates	drug	0.70
lipopolysaccharide	inhibits	drug	0.70
ALPHA-SYNUCLEIN	causes	protein	0.70
DRD2	causes	gene	0.70
levodopa	converts_to	drug	0.70
ALPHA-SYNUCLEIN	interacts_with	protein	0.70
TH	activates	gene	0.70
ALPHA-SYNUCLEIN	inhibits	protein	0.70
ginsenoside Rb1	regulates	drug	0.70
CHOLESTEROL	inhibits	phenotype	0.70
LC3	associated_with	protein	0.66
PARKIN	associated_with	gene	0.66
TH	inhibits	gene	0.65
SCHIZOPHRENIA	regulates	disease	0.65
LOCUS COERULEUS	causes	brain_region	0.65
TAU	protects_against	protein	0.65
INFLAMMATION	treats	phenotype	0.65

Targeting Hypotheses (12)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
NMN Supplementation Restores SIRT1/p66Shc/FOXO3 Epigenetic A	0.790	neurodegeneration	epigenetic reprogramming aging neurons
LAMP2A Liquid-Liquid Phase Separation Defects in Dopaminergi	0.783	neurodegeneration	-
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio	0.751	neuroscience	Circuit-level neural dynamics in neurode
GBA1 Loss Triggers a TFEB-to-TFE3 Compensatory Switch in A9	0.750	neurodegeneration	-
Chronic ISR Activation Represses Axonal Protein Synthesis in	0.650	parkinsons	-

BH4 Cofactor Restoration as Primary Driver of >500-Fold Dopa	0.618	neurodegeneration	What molecular mechanisms underlie Atrem
Correcting Gut Microbial Dopamine Imbalance to Support Syste	0.606	neurodegeneration	What are the mechanisms by which gut mic
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis	0.384	neurodegeneration	What are the mechanisms by which gut mic
Dopaminergic Ventral Tegmental-Striatal Circuit Protection	0.380	neuroscience	Circuit-level neural dynamics in neurode
TFEB Activation to Restore Lysosomal Biogenesis in Parkinson	0.380	proteomics	Quantitative proteomics of the aging syn
Dopaminergic Cognitive Enhancement Hypothesis	0.000	-	Unable to extract research questions - t
Prevotellaceae as Dopamine Precursor Modulators	0.000	-	Does reduced Prevotellaceae abundance ca

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (10)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Plasma ATN biomarkers across AD continuum in Chilean cohort	clinical	Alzheimer's disease	0.950	0.00	Chilean older adults (n=318) w	proposed	N/A
Epigenetic clocks association with brain aging patterns in older women	exploratory	cognitive impairment and demen	0.900	0.00	human patients	proposed	N/A
Tau depletion effects on neuronal development in primary cultures	exploratory		0.900	0.00	primary rodent neuronal cultur	proposed	N/A
Differential GWAS of schizophrenia vs PTSD	exploratory	schizophrenia, post-traumatic	0.900	0.00	human patients - European ance	proposed	N/A
Tau depletion effects on neuronal development in primary cultures	exploratory		0.900	0.00	primary rodent neuronal cultur	proposed	N/A
Creation and validation of 3xAD-ChAT-Cre mouse model	validation	Alzheimer's disease	0.900	0.00	3xAD-ChAT-Cre transgenic mice	proposed	N/A
GTEx brain tissue expression analysis of MAPT/CRHR1 locus	exploratory	schizophrenia, post-traumatic	0.850	0.00	human brain tissue samples fro	proposed	N/A
Microtubule domain analysis in adult axons	exploratory		0.800	0.00	adult rodent axons	proposed	N/A
Tau depletion effects on microtubule domains in adult axons	exploratory		0.800	0.00	adult rodent neurons	proposed	N/A
Levodopa-Induced Dyskinesias Mechanism — Experiment Design	validation	Neurodegeneration	0.400	0.50	human	proposed	$2,280,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders [PMID:41699128]	["Bolsewig K", "Bellomo G", "Hok-A-Hin Y	Nature medicine	2026
Gene therapy for Parkinson's disease: current landscape, translational challenge [PMID:41837837]	Evola V, Parmar MS	Expert review of neurotherapeu	2026
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by [PMID:39881147]	["Bolsewig K", "Willemse E", "S\u00e1nch	Nature communications	2025
Neurosurgical gene therapy for central nervous system diseases. [PMID:39191071]	Patel RV, Nanda P, Richardson RM	Neurotherapeutics : the journa	2024
Characterization of Vps13b-mutant mice reveals neuroanatomical and behavioral ph [PMID:37573958]	["Montillot C", "Skutunova E", "Ayushma"	Neurobiology of disease	2023
Interplay between the catecholaminergic enzymatic axis and neurodegeneration/neu [PMID:36692274]	["Motta C", "Assogna M", "Bonomi C", "Di	European journal of neurology	2023
Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC d [PMID:34763085]	Tai CH, Lee NC, Chien YH, Byrne BJ, Mura	Molecular therapy : the journa	2022
Gene therapy restores dopamine transporter expression and ameliorates pathology [PMID:34011628]	Ng J, Barral S, De La Fuente Barrigon C,	Science translational medicine	2021
Current Clinical Applications of In Vivo Gene Therapy with AAVs. [PMID:33309881]	Mendell JR, Al-Zaidy SA, Rodino-Klapac L	Molecular therapy : the journa	2021
Targeting autophagy using small-molecule compounds to improve potential therapy [PMID:34729301]	Zhang K, Zhu S, Li J, Jiang T, Feng L, P	Acta pharmaceutica Sinica. B	2021
Bi-allelic loss of function variants in SLC30A5 as cause of perinatal lethal car [PMID:33547425]	Lieberwirth JK, Joset P, Heinze A, Hents	European journal of human gene	2021
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Graphene bilayers with a twist. [PMID:33208935]	["Andrei E", "MacDonald A"]	Nature materials	2020
Reconstruction of cell spatial organization from single-cell RNA sequencing data [PMID:32541867]	["Ren X", "Zhong G", "Zhang Q", "Zhang L	Cell research	2020
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Environmental Regulation, Technological Innovation, and Export Competitiveness: [PMID:32102174]	Liu J, Xie J	International journal of envir	2020
Predicting Subjective Recovery from Lower Limb Surgery Using Consumer Wearables. [PMID:33442582]	Karas M, Marinsek N, Goldhahn J, Foschin	Digital biomarkers	2020
Gene therapy for neurodegenerative disorders: advances, insights and prospects. [PMID:32963936]	Chen W, Hu Y, Ju D	Acta pharmaceutica Sinica. B	2020

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning DOPAMINE in their description or question text

BH4 Cofactor Restoration as Primary Driver of >500-Fold Dopamine Elevation

Score: 0.618 · neurodegeneration · 2026-04-13

## Mechanistic Overview BH4 Cofactor Restoration as Primary Driver of >500-Fold Dopamine Elevation starts from the claim

Correcting Gut Microbial Dopamine Imbalance to Support Systemic Dopaminergic Fun

Score: 0.606 · neurodegeneration · 2026-04-02

## Mechanistic Overview Correcting Gut Microbial Dopamine Imbalance to Support Systemic Dopaminergic Function starts fro

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis

Score: 0.384 · neurodegeneration · 2026-04-02

Engineered probiotic bacteria expressing tyrosine hydroxylase and aromatic L-amino acid decarboxylase could produce L-DO

Dopaminergic Ventral Tegmental-Striatal Circuit Protection

Score: 0.380 · neuroscience · 2026-04-26

The dopaminergic ventral tegmental-striatal circuit protection hypothesis proposes that MAPT-encoded tau protein dysfunc

TFEB Activation to Restore Lysosomal Biogenesis in Parkinson's Disease Dopaminer

Score: 0.380 · proteomics · 2026-04-27

Age-related decline in lysosomal function contributes to the accumulation of pathological protein aggregates in Parkinso

Dopaminergic Cognitive Enhancement Hypothesis

Score: 0.000 · unknown disease · 2026-04-28

Selective modulation of prefrontal cortical dopamine through COMT inhibition enhances question extraction by optimizing

Prevotellaceae as Dopamine Precursor Modulators

Score: 0.000 · unknown disease · 2026-04-28

Prevotellaceae produce dopamine precursors; their depletion creates subclinical dopamine deficiency making neurons vulne